Back to Search
Start Over
Development of matrix metalloproteinase inhibitors in cancer therapy.
- Source :
-
Hematology/oncology clinics of North America [Hematol Oncol Clin North Am] 2002 Oct; Vol. 16 (5), pp. 1189-227. - Publication Year :
- 2002
-
Abstract
- The matrix metalloproteinases represent an attractive target for cancer treatment, and a number of matrix metalloproteinase inhibitors are undergoing clinical trials. The results of these studies will establish whether any of these compounds are therapeutically useful. Independent of the conclusions from the first generation of studies, the field of matrix metalloproteinase inhibitors remains attractive for creative and innovative research. In the future, the development of novel, less toxic, and more effective matrix metalloproteinase inhibitors, and the combination of conventional agents with these novel anticancer agents will constitute the main focus of research efforts.
- Subjects :
- Clinical Trials as Topic
Diphosphonates therapeutic use
Drug Design
Drug Screening Assays, Antitumor
Forecasting
Humans
Matrix Metalloproteinases physiology
Neoplasm Invasiveness
Neoplasm Proteins physiology
Neoplasms blood supply
Neoplasms enzymology
Protease Inhibitors therapeutic use
Tetracyclines therapeutic use
Matrix Metalloproteinase Inhibitors
Neoplasm Proteins antagonists & inhibitors
Neoplasms drug therapy
Protease Inhibitors pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 0889-8588
- Volume :
- 16
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Hematology/oncology clinics of North America
- Publication Type :
- Academic Journal
- Accession number :
- 12512389
- Full Text :
- https://doi.org/10.1016/s0889-8588(02)00044-8